Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase

Leukemia

Volumn 25, Issue 4, 2011, Pages 648-654

  Meisel, R ^a   Brockers, S ^a   Heseler, K ^a   Degistirici, O ^a   Bulle H ^a   Woite, C ^a   Stuhlsatz, S ^a   Schwippert, W ^a   Jager M ^a   Sorg, R ^a   Henschler, R ^b   Seissler, J ^c   Dilloo, D ^a,d   Daubener W ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

antimicrobial effector function; human; IDO; MSC; murine

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CYTOKINE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE;

ANIMAL; ARTICLE; BACTERIUM; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL; METABOLISM; MOUSE; MULTIPOTENT STEM CELL; PARASITOLOGY; PHYSIOLOGY; STROMA CELL; TOXOPLASMA; TOXOPLASMOSIS; VIROLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; BACTERIA; CELLS, CULTURED; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MULTIPOTENT STEM CELLS; NITRIC OXIDE SYNTHASE TYPE II; STROMAL CELLS; TOXOPLASMA; TOXOPLASMOSIS;

EID: 85027941877     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.310     Document Type: Article

References (31)

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–147. DOI: 10.1126/science.284.5411.143
2. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619–4621. DOI: 10.1182/blood-2003-11-3909
3. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327–1333. DOI: 10.1182/blood-2007-02-074997
4. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007; 110: 2764–2767. DOI: 10.1182/blood-2007-04-087056
5. Wolf D, Wolf AM. Mesenchymal stem cells as cellular immunosuppressants. Lancet 2008; 371: 1553–1554. DOI: 10.1016/S0140-6736(08)60666-2
6. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499–3506. DOI: 10.1182/blood-2007-02-069716
7. Kang HS, Habib M, Chan J, Abavana C, Potian JA, Ponzio NM et al. A paradoxical role for IFN-gamma in the immune properties of mesenchymal stem cells during viral challenge. Exp Hematol 2005; 33: 796–803. DOI: 10.1016/j.exphem.2005.03.012
8. Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Le Blanc K. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant 2006; 37: 1051–1059. DOI: 10.1038/sj.bmt.1705368
9. Deak E, Ruster B, Keller L, Eckert K, Fichtner I, Seifried E et al. Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice. Cytotherapy 2010; 12: 260–264. DOI: 10.3109/14653240903401840
10. Tropel P, Noel D, Platet N, Legrand P, Benabid AL, Berger F. Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. Exp Cell Res 2004; 295: 395–406. DOI: 10.1016/j.yexcr.2003.12.030
11. Daubener W, Wanagat N, Pilz K, Seghrouchni S, Fischer HG, Hadding U. A new, simple, bioassay for human IFN-gamma. J Immunol Methods 1994; 168: 39–47. DOI: 10.1016/0022-1759(94)90207-0
12. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 1988; 141: 2407–2412.
13. Schroten H, Spors B, Hucke C, Stins M, Kim KS, Adam R et al. Potential role of human brain microvascular endothelial cells in the pathogenesis of brain abscess: inhibition of Staphylococcus aureus by activation of indoleamine 2,3-dioxygenase. Neuropediatrics 2001; 32: 206–210. DOI: 10.1055/s-2001-17375
14. Daubener W, Spors B, Hucke C, Adam R, Stins M, Kim KS et al. Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase. Infect Immun 2001; 69: 6527–6531. DOI: 10.1128/IAI.69.10.6527-6531.2001
15. Adams O, Besken K, Oberdorfer C, MacKenzie CR, Takikawa O, Daubener W. Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections. J Virol 2004; 78: 2632–2636. DOI: 10.1128/JVI.78.5.2632-2636.2004
16. Parsons CH, Szomju B, Kedes DH. Susceptibility of human fetal mesenchymal stem cells to Kaposi sarcoma-associated herpesvirus. Blood 2004; 104: 2736–2738. DOI: 10.1182/blood-2004-02-0693
17. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228–234. DOI: 10.1182/blood-2006-02-002246
18. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141–150. DOI: 10.1016/j.stem.2007.11.014
19. Muller A, Heseler K, Schmidt SK, Spekker K, Mackenzie CR, Daubener W. The missing link between indoleamine 2,3-dioxygenase mediated antibacterial and immunoregulatory effects. J Cell Mol Med 2009; 13: 1125–1135. DOI: 10.1111/j.1582-4934.2008.00542.x
20. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815–1822. DOI: 10.1182/blood-2004-04-1559
21. Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, Favrot MC. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19: 1597–1604. DOI: 10.1038/sj.leu.2403871
22. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386–398. DOI: 10.1634/stemcells.2005-0008
23. Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 2007; 179: 1595–1604. DOI: 10.4049/jimmunol.179.3.1595
24. Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, Levacher B et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006; 176: 7761–7767. DOI: 10.4049/jimmunol.176.12.7761
25. Badillo AT, Peranteau WH, Heaton TE, Quinn C, Flake AW. Murine bone marrow derived stromal progenitor cells fail to prevent or treat acute graft-versus-host disease. Br J Haematol 2008; 141: 224–234. DOI: 10.1111/j.1365-2141.2008.07040.x
26. Prigozhina TB, Khitrin S, Elkin G, Eizik O, Morecki S, Slavin S. Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. Exp Hematol 2008; 36: 1370–1376. DOI: 10.1016/j.exphem.2008.04.022
27. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579–1586. DOI: 10.1016/S0140-6736(08)60690-X
28. Kaandorp CJ, Dinant HJ, van de Laar MA, Moens HJ, Prins AP, Dijkmans BA. Incidence and sources of native and prosthetic joint infection: a community based prospective survey. Ann Rheum Dis 1997; 56: 470–475. DOI: 10.1136/ard.56.8.470
29. Sia IG, Berbari EF. Infection and musculoskeletal conditions: osteomyelitis. Best Pract Res Clin Rheumatol 2006; 20: 1065–1081. DOI: 10.1016/j.berh.2006.08.014
30. Muller I, Vaegler M, Holzwarth C, Tzaribatchev N, Pfister SM, Schutt B et al. Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis. Leukemia 2008; 22: 2054–2061. DOI: 10.1038/leu.2008.217
31. Hebart H, Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 2004; 65: 432–436. DOI: 10.1016/j.humimm.2004.02.022